This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 May 3;327(17):1653-1655.

doi: 10.1001/jama.2022.5333.

The Potential Clinical Benefit of Lowering Lipoprotein(a)

Brian A Ference¹

Affiliations

PMID: 35368050
DOI: 10.1001/jama.2022.5333

Comment

The Potential Clinical Benefit of Lowering Lipoprotein(a)

Brian A Ference. JAMA. 2022.

. 2022 May 3;327(17):1653-1655.

doi: 10.1001/jama.2022.5333.

Author

Brian A Ference¹

Affiliation

¹ Centre for Naturally Randomized Trials, University of Cambridge, Cambridge, England.

PMID: 35368050
DOI: 10.1001/jama.2022.5333

No abstract available

PubMed Disclaimer

Comment on

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, Wilson RJ, Boyce M, Ray KK, Cho L, Watts GF, Koren M, Turner T, Stroes ES, Melgaard C, Campion GV. Nissen SE, et al. JAMA. 2022 May 3;327(17):1679-1687. doi: 10.1001/jama.2022.5050. JAMA. 2022. PMID: 35368052 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems